Diagnostic tools for response to 6-thiopurine therapy
View Patent ↗NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
1. A method for treating a patient having a chronic inflammatory disease, the method comprising administering a 6-thiopurine or 6-thioguanine treatment regimen to the patient having the chronic inflammatory disease,
wherein the patient is determined have a KIR/HLA-haplotype of an AA haplotype, homozygous for HLA-C1 and present for Bw6; a non-AA haplotype, present for KIR2DL2 and homozygous for HLA-C1; a non-AA haplotype, present for KIR2DL2 and heterozygous for HLA-C1/HLA-C2; or a non-AA haplotype, absent for KIR2DL2 and homozygous for HLA-C1, based on a KIR/HLA haplotype determination of the patient, and
wherein the KIR/HLA-haplotype of the patient is determined by:
(a) providing a biological sample from the patient;
(b) obtaining nucleic acid from the biological sample; and
(c) hybridizing the nucleic acid, to:
(i) a first solid support comprising synthetic capture probes selective for KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, KIR2DP1, KIR3DP1, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1; and
(ii) a second solid support comprising capture probes selective for HLA-C1, HLA-C2, HLA-Bw4 and HLA-Bw6.
2. The method of claim 1 , wherein the biological sample is a blood sample.
3. The method of claim 1 , wherein the patient is a human.
4. The method of claim 1 , wherein the treatment regimen is a 6-thioguanine treatment regimen.